3rd EASL Hepatocellular Carcinoma (HCC) Summit: From basic to clinical research: How to improve HCC clinical care?
OVERVIEW
3rd EASL Hepatocellular Carcinoma (HCC) Summit: From basic to clinical research: How to improve HCC clinical care? is organized by European Association for the Study of the Liver (EASL) and will be held during Mar 01 - 03, 2018 at Starling Hotel Geneva, Le grand-saconnex, Geneve, Switzerland.
The target audience for this medical event is Hepatologists, Physicians with interest in liver cancer, Young researchers and trainees, Basic and translational scientists, Clinical researchers, Health professionals, Industry. This CME Conference has been approved for a maximum of 17 Credits.
Conference Description :
HCC is considered one of the most important causes of death in patients affected with chronic liver disease. In the past years, major advances in the early diagnosis and treatment, particularly in advanced stages, have taken place.
This Summit will cover both the basic and translational/clinical aspects of the disease, with a specific focus on new targeted therapies in HCC. Great efforts have been made in the scientific programme to enhance the interaction among basic scientists, clinical researchers, and Industry leaders to stimulate our combined efforts in addressing the key challenges in HCC.
This year’s programme will be informative and stimulating, covering a broad range of topics presented as high-quality presentations by renowned experts. We anticipate that this combination of high quality and interactive presentations by leading scientists and clinicians from academia and industry will be successful, and will help to move the field forward.
• 3 days of cutting edge basic and clinical research on liver cancer.
• Latest in clinical care and patient management.
• Showcase your research, gather and network with renowned scientists and leading experts.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Hepatologists, Physicians with interest in liver cancer, Young researchers and trainees, Basic and translational scientists, Clinical researchers, Health professionals, Industry. This CME Conference has been approved for a maximum of 17 Credits.
Conference Description :
HCC is considered one of the most important causes of death in patients affected with chronic liver disease. In the past years, major advances in the early diagnosis and treatment, particularly in advanced stages, have taken place.
This Summit will cover both the basic and translational/clinical aspects of the disease, with a specific focus on new targeted therapies in HCC. Great efforts have been made in the scientific programme to enhance the interaction among basic scientists, clinical researchers, and Industry leaders to stimulate our combined efforts in addressing the key challenges in HCC.
This year’s programme will be informative and stimulating, covering a broad range of topics presented as high-quality presentations by renowned experts. We anticipate that this combination of high quality and interactive presentations by leading scientists and clinicians from academia and industry will be successful, and will help to move the field forward.
• 3 days of cutting edge basic and clinical research on liver cancer.
• Latest in clinical care and patient management.
• Showcase your research, gather and network with renowned scientists and leading experts.
Additional details will be posted as soon as they are available.
KEY DATES
01 Mar, 2018
Event Start Date
03 Mar, 2018
Event End Date
SPECIALITIES
OncologySUGGESTED HOTELS
CONFERENCE VENUE
Starling Hotel GenevaRELATED CONFERENCES & LIVE WEBINARS
Quick Links